Journal of Translational Medicine最新文献

{"title":"The global burden and biomarkers of cardiovascular disease attributable to ambient particulate matter pollution.","authors":"Haoxian Tang, Jingtao Huang, Hanyuan Lin, Xuan Zhang, Qinglong Yang, Nan Luo, Mengyue Lin, Cuihong Tian, Shiwan Wu, Jianan Hong, Jiasheng Wen, Liwen Jiang, Pan Chen, Xiaojing Chen, Junshuang Tang, Youti Zhang, Kaihong Yi, Xuerui Tan, Yequn Chen","doi":"10.1186/s12967-025-06375-9","DOIUrl":"10.1186/s12967-025-06375-9","url":null,"abstract":"<p><strong>Background: </strong>Understanding the evolving patterns of cardiovascular disease (CVD) burden attributable to ambient particulate matter pollution (APMP) is essential. Furthermore, research on the underlying mechanisms has mostly been limited to laboratory and animal models, with few large-scale population-based studies.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease Study (GBD) 2021, we analyzed disability-adjusted life years and mortality for CVD attributable to APMP (measured as particulate matter [PM]_2.5) from 1990 to 2021. We examined shifts in burden between APMP and household air pollution (HAP), regional disparities by socio-demographic index (SDI), and predicted trends using a Bayesian age-period-cohort model. Additionally, we used UK Biobank (UKB) data (metabolomics: 230,000 + participants; proteomics: 50,000 +) to identify biomarkers mediating the association between PM_2.5 exposure and CVD outcomes, and further analyzed their biological roles. Metabolic and proteomic signatures were constructed using regression and elastic net models, with predictive performance assessed via time-dependent receiver operating characteristic analysis. Life expectancy was evaluated using flexible parametric survival models. Subgroup analysis was conducted by age, sex, lifestyle, socioeconomic status, and genetic susceptibility.</p><p><strong>Results: </strong>In 2021, the global CVD absolute burden attributable to APMP was more than double that of 1990, with significant regional disparities. The burden shifted from HAP to APMP, with 15% of CVD cases globally attributed to APMP. The CVD burden attributable to APMP increased with age and is projected to rise through 2030. In the UKB, approximately 30 metabolites, including albumin, mediated the association between PM_2.5 exposure and CVD outcomes, primarily involving lipid and fatty acids metabolism. Over 60 proteins, including growth differentiation factor-15 and trefoil factor 2, mediated the association with CVD outcomes, enriched in cytokine-receptor interaction and leukocyte migration pathways. Metabolic and proteomic signatures outperformed PM_2.5 alone in predicting 1-, 5-, and 10-year CVD outcomes. Participants in the lowest decile of PM_2.5 exposure, metabolic, and proteomic signatures had longer life expectancy than those in the highest decile.</p><p><strong>Conclusion: </strong>The CVD burden attributable to APMP remains a critical public health concern. This study presents a novel approach for identifying and managing susceptible populations through metabolomic and proteomic perspectives.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"359"},"PeriodicalIF":6.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating single-cell and bulk RNA sequencing data to characterize the heterogeneity of glycan-lipid metabolism polarization in hepatocellular carcinoma.","authors":"Peng Lin, Qiong Qin, Xiang-Yu Gan, Jin-Shu Pang, Rong Wen, Yun He, Hong Yang","doi":"10.1186/s12967-025-06347-z","DOIUrl":"10.1186/s12967-025-06347-z","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is high heterogeneity and remains an unmet medical challenge, but their metabolic heterogeneity has not been fully uncovered and required clinical applicable translational strategies.</p><p><strong>Methods: </strong>By analyzing the RNA sequencing data in the in-house cohort and public HCC cohorts, we identified a metabolic subtype of HCC associated with multi-omics features and prognosis. Multi-omics alterations and clinicopathological information between different subtypes were analyzed. Gene signature, radiomics, contrast-enhanced ultrasound (CEUS), serum biomarkers were tested as potential surrogate methods for high throughput technology-based subtyping. Single-cell RNA sequencing analyses were employed to evaluate the immune characteristics changes between subtypes.</p><p><strong>Results: </strong>By utilizing metabolic-related pathways, we identified two heterogeneous metabolic HCC subtypes, glycan-HCC and lipid-HCC, with distinct multi-omics features and prognosis. Kaplan-Meier and restricted mean survival time analyses revealed worse overall survival in glycan-HCCs. And glycan-HCCs were characterized with high genomic instability, proliferation-related pathways activation and exhausted immune microenvironment. Furthermore, we developed gene signatures, radiomics, CEUS and serum biomarkers for subtypes determination, which showed substantial agreement with high-throughput-based classification. Single-cell RNA-seq showed glycan-HCCs were associated with multifaceted immune distortion, including exhaustion of T cells and enriched SPP1 + macrophages.</p><p><strong>Conclusion: </strong>Collectively, our analysis demonstrated the metabolic heterogeneity of HCCs and enabled the development of clinical translation strategies, thus promoting understanding and clinical applications about HCC metabolism heterogeneity.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"358"},"PeriodicalIF":6.1,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CHI3L1 mediates radiation resistance in colorectal cancer by inhibiting ferroptosis via the p53/SLC7A11 pathway.","authors":"Ming Jin, Hui Liu, Zhen Zheng, Shuai Fang, Yang Xi, Kaitai Liu","doi":"10.1186/s12967-025-06378-6","DOIUrl":"10.1186/s12967-025-06378-6","url":null,"abstract":"<p><strong>Background: </strong>Radiotherapy is a key treatment for colorectal cancer (CRC), particularly rectal cancer; however, many patients are resistant to radiation. While it has been shown that CHI3L1 is associated with CRC progression, its specific function and regulatory mechanisms in radiation resistance remain unclear.</p><p><strong>Methods: </strong>The levels of CHI3L1 in CRC and normal tissue samples were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. To assess the effects of CHI3L1 on CRC cell proliferative, migratory, and invasive capacities, Cell Counting Kit-8 (CCK-8) and Transwell assays were performed. Radiation resistance in CRC cells with varying CHI3L1 expression levels was evaluated through colony formation assay. Western blot and immunofluorescence analyses were conducted to explore the correlation between CHI3L1 and p53 expression levels. Ferroptosis was assessed by determining reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH) concentrations in cells with different CHI3L1 expression levels, and a xenograft mouse model was used to identify the molecular mechanisms of ferroptosis in vivo.</p><p><strong>Results: </strong>Significant CHI3L1 upregulated was observed in CRC tissues and was associated with promotion of malignant cell behaviors. The number of colonies in CHI3L1-overexpressing groups was significantly greater than that in the control groups following radiation, indicating increased radiation resistance in the former group. Furthermore, CHI3L1 overexpression was associated with p53 downregulation and elevated p53 ubiquitination. Notably, CHI3L1 inhibited the ferroptosis of CRC cells by suppressing p53 expression through the p53/SLC7A11 signaling pathway.</p><p><strong>Conclusions: </strong>CHI3L1 overexpression promotes the proliferation, migration, invasion, and radiation resistance of CRC cells. Elevated CHI3L1 expression is associated with increased p53 ubiquitination and SLC7A11 upregulation. CHI3L1 promotes radiation resistance by suppressing ferroptosis in CRC cells through the p53/SLC7A11 axis.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"357"},"PeriodicalIF":6.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do cancer survivors have an increased risk of developing subsequent cancer? A population-based study.","authors":"Yubo Wang, Yining Jiang, Yang Bai, Haiyang Xu","doi":"10.1186/s12967-025-06379-5","DOIUrl":"10.1186/s12967-025-06379-5","url":null,"abstract":"<p><strong>Background: </strong>The number of cancer survivors has steadily increased due to earlier detection and more effective therapies. Do all types of cancer survivors have an increased risk of developing subsequent cancers compared with the general population?</p><p><strong>Methods: </strong>Patients diagnosed with malignant cancer between January 2000 and December 2021 were included from the SEER 17 Registries (excl AK) database. Events were defined as subsequent cancer at any site according to ICD-O-3/WHO 2008. The observed and expected numbers of subsequent cancers were retrieved, and observed/expected (O/E) ratios and excess risks were calculated to assess the risk of developing subsequent cancers in cancer survivors compared with the United States general population within the same period. We obtained standard incidence ratios for the entire cohort and stratified the data by demographics, treatment, and cancer type.</p><p><strong>Results: </strong>Our findings indicate that compared with the general population, cancer survivors have a 16% greater risk of developing subsequent cancers (p < 0.05). All the subgroups also presented a significantly greater risk of developing subsequent cancers, even after stratification by demographics, treatment, and historic stage. Male patients with prostate cancer had a 31% lower risk of developing subsequent cancers, whereas female patients with lung and bronchus cancer presented a 93% increased risk.</p><p><strong>Conclusion: </strong>Our findings suggest that nearly all groups of cancer survivors experienced a significantly increased risk of developing subsequent cancers, whereas men with prostate cancer presented a 31% lower risk. These differential risks provide clinicians with evidence-based suggestions for tailored surveillance and prevention strategies. .</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"355"},"PeriodicalIF":6.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the protective effect of metformin against sarcopenia: insights from cohort studies and genetics.","authors":"Yanyan Hu, Shan Lu, Cheng Xue, Zhaonian Hu, Yifei Wang, Wensong Zhang, Dan Wang, Jizheng Wang, Guoxian Ding, Jing Yu, Yifang Hu, Yun Liu","doi":"10.1186/s12967-025-06357-x","DOIUrl":"10.1186/s12967-025-06357-x","url":null,"abstract":"<p><strong>Background: </strong>The impact of metformin on sarcopenia remains uncertain. This study aimed to investigate whether metformin influences sarcopenia risk and evaluate the effects of potential drug targets on sarcopenia traits.</p><p><strong>Methods: </strong>We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (n = 3549) to assess the association between metformin use and sarcopenia risk in elderly patients with type 2 diabetes. Mendelian randomization (MR) analysis using genome-wide association studies (GWAS) from UK Biobank (n = 1,366,167) and FinnGen (n = 218,007), with expression quantitative trait loci (eQTL) as instrumental variables, examined the causal effect of metformin-related targets on sarcopenia traits, while molecular docking explored the interaction between metformin and its drug targets.</p><p><strong>Results: </strong>Metformin use was associated with increased grip strength (OR = 2.46; 95% CI 1.49-2.38) and skeletal muscle mass (OR = 1.24; 95% CI 0.20-2.28), as well as reduced mortality (HR = 0.62; 95% CI 0.54-0.71). MR analysis suggested a possible link between GDF15 gene expression and sarcopenia traits, with no evidence of genetic confounding. Molecular docking indicated stable binding between metformin and GDF15.</p><p><strong>Conclusion: </strong>This study suggests that metformin may lower sarcopenia risk, particularly in elderly patients with type 2 diabetes, with GDF15 identified as a promising target for sarcopenia treatment.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"356"},"PeriodicalIF":6.1,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between adjustable dietary factors and periodontitis: NHANES 2009-2014 and Mendelian randomization.","authors":"Li Chen, Rui Zhao, Yarong Zhang","doi":"10.1186/s12967-024-05972-4","DOIUrl":"10.1186/s12967-024-05972-4","url":null,"abstract":"<p><strong>Background: </strong>Periodontitis is the major cause of tooth loss in adults and one of the most common non-communicable diseases. Clinically, periodontitis impairs oral health and associated with various systemic diseases. Maintaining a healthy diet is considered risk reduction of periodontitis. To explore the causal effect between dietary data and periodontitis by Mendelian randomization (MR) analyses.</p><p><strong>Methods: </strong>A total of 11,704 participants and 21 dietary variables from the NHANES were in random forest to rank the importance in predicting periodontitis. Data were from the genome wide association studies (GWASs) database to estimate causal relationships between diet data and periodontitis. Two-sample MR analyses were conducted by using the inverse-variance weighted (IVW) method.</p><p><strong>Results: </strong>The MR showed alcohol consumption and sugars intake increased the risk of chronic periodontitis with odds ratio (OR) 2.768 (95% CI: 1.03e + 00-7.42e + 00) and 2.123 (95% CI: 1.06e + 00-4.26e + 00) respectively. Vitamins and minerals, including folic acid and folate, magnesium, vitamin A, vitamin E, vitamin C, calcium, vitamin D and zinc, were not causally associated with chronic periodontitis. Alcohol consumption greater than 2.5 drinks per day and sugar intake more than 4.88 g increased the risk of periodontitis, with a calculated relative risk of 1.33 and 1.61, respectively.</p><p><strong>Conclusion: </strong>It is suggested to drink alcohol less than 2.5 drinks/day and consume sugar less than 4.88 g/day to avoid alcohol and sugar consumption promoting the development of periodontitis. Establishing a dietary pattern conducive to periodontal health may be the focus of further clinical research.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"353"},"PeriodicalIF":6.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A strategy for synergistic enhancement of immune circulation in head and neck squamous cell carcinoma by novel nucleic acid drug therapy and immunotherapy.","authors":"Yangjian Hong, Yanyang Liu, Huize Shen, Bowen Li, Qinglin Li","doi":"10.1186/s12967-025-06344-2","DOIUrl":"10.1186/s12967-025-06344-2","url":null,"abstract":"<p><p>Studies have shown that in the pathogenesis of head and neck squamous cell carcinoma, immune circulation obstruction caused by various factors including metabolic abnormalities, gene mutations, and matrix barrier, is a critical factor for the induction of tumor development and progression. Therefore, the immunotherapy strategy of killing head and neck squamous cell carcinoma cells by an enhanced immune circulation mechanism has attracted much attention. In addition, the rapid development of new nucleic acid drug therapy, such as mRNA, oligonucleotide and small guide RNA (sgRNA), has taken immunotherapy of head and neck squamous cell carcinoma (immune checkpoint inhibitors, tumor vaccines, cellular immunotherapy, cytokines and adjuvants, etc.) to a new level. The combination of nucleic acid therapy with immunotherapy developed for its therapeutic properties has brought a new direction for the diagnosis and treatment of head and neck squamous cell carcinoma, and the combination of the two has had considerable curative effect to patients with refractory/recurrent head and neck squamous cell carcinoma. In this review, we summarized the latest progress of nucleic acid therapy applied to conventional immunotherapy for head and neck squamous cell carcinoma, discussed its mechanism of action and efficacy, and looked into the future development trend.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"354"},"PeriodicalIF":6.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11927285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intratumoral microbiota-aided fusion radiomics model for predicting tumor response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer.","authors":"Yilin Chen, Yuhong Huang, Wei Li, Teng Zhu, Minyi Cheng, Cangui Wu, Liulu Zhang, Hao Peng, Kun Wang","doi":"10.1186/s12967-025-06369-7","DOIUrl":"10.1186/s12967-025-06369-7","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoimmunotherapy (NACI) has emerged as the standard treatment for early-stage triple-negative breast cancer (TNBC). However, reliable biomarkers for identifying patients who are likely to benefit from NACI are lacking. This study aims to develop an intratumoral microbiota-aided radiomics model for predicting pathological complete response (pCR) in patients with TNBC.</p><p><strong>Methods: </strong>Intratumoral microbiota are characterized by 16S rDNA sequencing and quantified through experimental assays. Single-cell RNA sequencing is performed to analyze the tumor microenvironment of tumors with various responses to NACI. Radiomics features are extracted from tumor regions on longitudinal magnetic resonance images (MRIs) scanned before and after NACI in the training set. On the basis of treatment response (pCR or non-pCR) and intratumoral microbiota scoring, we select key radiomics features and construct a fusion model integrating multi-timepoint (pre-NACI and post-NACI) MRI to predict the efficacy of immunotherapy, followed by independent external validation.</p><p><strong>Results: </strong>A total of 124 patients are enrolled, with 88 in the training set and 36 in the validation set. Tumors from patients who achieves pCR present a significantly greater intratumoral microbiota load than tumors from patients who achieve non-pCR (p < 0.05). Additionally, tumors in non-pCR group exhibit greater infiltration of tumor-associated SPP1⁺ macrophages, which is negatively correlated with the microbiota load. On the basis of intratumoral microbiota scoring, we select 17 radiomics features and use them to construct the fusion radiomics model. The fusion model achieves the highest AUC of 0.945 in the training set, outperforming pre-NACI (AUC = 0.875) and post-NACI (AUC = 0.917) models. In the validation set, this model maintains a superior AUC of 0.873, surpassing those of pre-NACI (AUC = 0.769) and post-NACI (AUC = 0.802) models. Clinically, the fusion model distinguishes patients who achieve pCR from those who do not with an accuracy of 77.8%. Decision curve analysis demonstrates the superior net clinical benefit of this model across varying risk thresholds.</p><p><strong>Conclusions: </strong>Our intratumoral microbiota-aided radiomics model could serve as a powerful and noninvasive tool for predicting the response of patients with early-stage TNBC to NACI.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"352"},"PeriodicalIF":6.1,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic vivax malaria is associated with an IFN-γ-program on adaptive immunity.","authors":"Gregório Guilherme Almeida, Camila Medeiros Costa, Pedro Augusto Carvalho Costa, Gabriela Ribeiro Gomes, Maria Marta Figueiredo, Katherine Jéssica Torres, Alex Fiorini de Carvalho, Bruno Vinícius Santos Valiate, Julia Ramos Sampaio, Brener Cunha Carvalho, Dhelio Batista Pereira, Alexia Martines, Mauro Shugiro Tada, Irene Silva Soares, Jamie Ponmattam, Marcia Caldas de Castro, Douglas Taylor Golenbock, Ricardo Tostes Gazzinelli, Lis Ribeiro do Valle Antonelli","doi":"10.1186/s12967-025-06353-1","DOIUrl":"10.1186/s12967-025-06353-1","url":null,"abstract":"<p><p>The adaptive immunity against Plasmodium vivax is thought to be essential to limit parasite growth during asymptomatic malaria, preventing the occurrence of symptoms. However, the mechanisms governing clinical immunity during asymptomatic infections are not understood. Here, we investigated the adaptive cellular compartment in asymptomatic P. vivax-infected individuals (ASY) compared to symptomatic patients (SY) and healthy donors (CTL). Our integrative analysis revealed a T_H1-biased immune signature with expanded populations of T_H1 CD4⁺ T cells associated with the asymptomatic infection. In addition, there is an expanded population of proliferating atypical memory B cells that correlate with IgG levels against P. vivax antigens and parasitemia. The absence of systemic inflammation based on a comprehensive panel of soluble markers and the lower expression of some regulatory markers suggests a controlled inflammatory response that can be derived from an effective control of parasite growth. Our findings suggest that ASY maintain a pool of IFN-γ-associated Th cell phenotypes that orchestrate the immune response, limiting parasitemia and preventing clinical malaria.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"351"},"PeriodicalIF":6.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From virtual to reality: innovative practices of digital twins in tumor therapy.","authors":"Shiying Shen, Wenhao Qi, Xin Liu, Jianwen Zeng, Sixie Li, Xiaohong Zhu, Chaoqun Dong, Bin Wang, Yankai Shi, Jiani Yao, Bingsheng Wang, Louxia Jing, Shihua Cao, Guanmian Liang","doi":"10.1186/s12967-025-06371-z","DOIUrl":"10.1186/s12967-025-06371-z","url":null,"abstract":"<p><strong>Background: </strong>As global cancer incidence and mortality rise, digital twin technology in precision medicine offers new opportunities for cancer treatment.</p><p><strong>Objective: </strong>This study aims to systematically analyze the current applications, research trends, and challenges of digital twin technology in tumor therapy, while exploring future directions.</p><p><strong>Methods: </strong>Relevant literature up to 2024 was retrieved from PubMed, Web of Science, and other databases. Data visualization was performed using R and VOSviewer software. The analysis includes the research initiation and trends, funding models, global research distribution, sample size analysis, and data processing and artificial intelligence applications. Furthermore, the study investigates the specific applications and effectiveness of digital twin technology in tumor diagnosis, treatment decision-making, prognosis prediction, and personalized management.</p><p><strong>Results: </strong>Since 2020, research on digital twin technology in oncology has surged, with significant contributions from the United States, Germany, Switzerland, and China. Funding primarily comes from government agencies, particularly the National Institutes of Health in the U.S. Sample size analysis reveals that large-sample studies have greater clinical reliability, while small-sample studies emphasize technology validation. In data processing and artificial intelligence applications, the integration of medical imaging, multi-omics data, and AI algorithms is key. By combining multimodal data integration with dynamic modeling, the accuracy of digital twin models has been significantly improved. However, the integration of different data types still faces challenges related to tool interoperability and limited standardization. Specific applications of digital twin technology have shown significant advantages in diagnosis, treatment decision-making, prognosis prediction, and surgical planning.</p><p><strong>Conclusion: </strong>Digital twin technology holds substantial promise in tumor therapy by optimizing personalized treatment plans through integrated multimodal data and dynamic modeling. However, the study is limited by factors such as language restrictions, potential selection bias, and the relatively small number of published studies in this emerging field, which may affect the comprehensiveness and generalizability of our findings. Moreover, issues related to data heterogeneity, technical integration, and data privacy and ethics continue to impede its broader clinical application. Future research should promote international collaboration, establish unified interdisciplinary standards, and strengthen ethical regulations to accelerate the clinical translation of digital twin technology in cancer treatment.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":"23 1","pages":"348"},"PeriodicalIF":6.1,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}